Goldman Sachs
RSLS

Goldman Sachs’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Goldman Sachs’s Portfolio RSLS Stock Details RSLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11
Closed -$33K – 6620
2017
Q4 		$33K Buy
+11
New +$36.4K ﹤0.01% 6031

Other funds holding RSLS

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs's RSLS Position: Q1 2018 in Review

Goldman Sachs sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q1 2018, closing a stake of 11 shares — an estimated $33K sold.

Goldman Sachs first reported a position in RSLS in Q4 2017 and held it in 1 quarter. The position peaked at $33K in Q4 2017. 12 funds tracked by Wall St. Rank hold RSLS as of Q1 2018.

  • Goldman Sachs reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 11 ReShape Lifesciences Inc. Common Stock shares in Q1 2018, an estimated $33K.
  • Goldman Sachs first reported a position in ReShape Lifesciences Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Goldman Sachs's ReShape Lifesciences Inc. Common Stock position peaked at $33K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.